Previous close | 282.40 |
Open | 286.20 |
Bid | 285.80 x 0 |
Ask | 286.40 x 0 |
Day's range | 284.00 - 289.80 |
52-week range | 255.00 - 554.00 |
Volume | |
Avg. volume | 123,939 |
Market cap | 4.974B |
Beta (5Y monthly) | 1.20 |
PE ratio (TTM) | 34.64 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 6.00 (2.12%) |
Ex-dividend date | 13 Oct 2023 |
1y target est | N/A |
ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million. Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in
ANNOUNCEMENT NO. 260 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 9 April 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of the Capital Markets Act. The
ANNOUNCEMENT NO. 259 Major shareholder announcement Major shareholder announcement – Swedbank Robur Fonder AB Pursuant to Section 38 of the Danish Capital Markets Act, it is hereby announced that Swedbank Robur Fonder AB has informed ChemoMetec A/S that Swedbank Robur Fonder AB on 2 April 2024, decreased its holding of shares and voting rights to below 5% of the total share capital and voting rights in ChemoMetec A/S. Additional information Niels Høy Nielsen, CFOTelephone (+45) 2551 8724 About C